For a life sciences company that already books real revenue — a diagnostics lab billing payers, a CRO invoicing sponsors, a device distributor moving product, a CDMO running batches — the most practical "line of credit" is usually a revenue-based line of financing through an MCA marketplace, where approval turns on your bank deposits and revenue trend rather than your FICO or years of profitability. It typically starts around $10,000, accepts owner credit down to roughly 500 FICO, and funds in 24-48 hours once statements are in. It is not the right tool for a pre-revenue clinical-stage biotech living on grants and equity — that's a venture-debt or dilutive-capital conversation. But for the operating side of life sciences, where cash is real but lumpy, it fills the gap a bank line leaves open: reimbursement that lands 60-90 days after you've already paid for reagents, labor, and instrument time.
Key takeaways
- Best fit for revenue-generating life sciences (diagnostics labs, CROs, device distributors, CDMOs, research tools) — not pre-revenue clinical-stage biotech.
- Approval is driven by business bank deposits and revenue trend, not FICO or trailing profitability.
- Minimum around $10,000; owner FICO accepted down to roughly 500.
- Typical funding in 24-48 hours after complete bank statements are submitted.
- Repayment is a fixed share of deposits that reconciles with revenue, so it flexes with reimbursement timing.
- Document ask is short: 3-6 months of bank statements, one-page application, basic KYC; no collateral appraisal or covenant package.
- No legitimate funder guarantees approval — deposits decide, and 'guaranteed' is a red flag.
Why life sciences cash flow breaks the standard bank line
Life sciences companies live inside a timing mismatch that a conventional bank line is poorly built to absorb. You buy reagents, consumables, and instrument time now; you bill a payer, a hospital system, or a pharma sponsor now; and the money arrives 45, 60, or 90 days later — sometimes after a denial-and-resubmit cycle. Meanwhile payroll for PhD-level scientists and licensed techs runs every two weeks regardless.
Banks underwrite that gap on collateral and trailing profitability. A lot of otherwise healthy life sciences shops fail that test for reasons that have nothing to do with viability: heavy R&D expensing that suppresses net income, a short operating history after a spinout, revenue concentrated in a few large sponsors, or a balance sheet dominated by specialized equipment a bank won't lend against. From an underwriter's chair, none of those are disqualifying — they're just cash-flow shapes. Revenue-based financing reads the shape directly: consistent deposits, a stable-to-growing revenue trend, and a bank account that doesn't routinely go negative.
What a revenue-based line actually is (and isn't)
A revenue-based line through an MCA marketplace advances a lump sum against your future receipts, then reconciles a small fixed share of your deposits — daily or weekly — until the agreed amount is satisfied. Because repayment is a percentage of what comes in, it flexes with your revenue: slow reimbursement week, smaller remittance. It behaves like working capital that self-adjusts to cash flow, which is exactly the pressure point in life sciences.
What it isn't: it is not venture debt, not an equipment loan, not a grant advance, and not equity. It doesn't dilute your cap table and it doesn't require a lead investor's blessing. It's also not the cheapest capital on the menu — the cost of speed and flexibility is a higher effective rate than a secured bank line. Use it for timing gaps you can see closing, not to fund a multi-year R&D runway. For the mechanics of how these advances price and reconcile, see our merchant cash advance overview.
Who inside life sciences this fits
The label "life sciences" covers wildly different cash profiles. Revenue-based financing fits the operating, revenue-generating segments — and doesn't fit the pre-revenue research segment. From an underwriting standpoint:
| Segment | Cash profile | Revenue-based line fit |
|---|---|---|
| Clinical diagnostics / reference lab | Steady payer & client billings, reimbursement lag | Strong — deposits are regular |
| CRO / research services | Milestone or monthly sponsor invoicing | Strong when billings are recurring |
| Medical device distribution / resale | Purchase-order driven, inventory-heavy | Good — bridges PO-to-payment |
| CDMO / contract manufacturing | Batch revenue, deposits on order | Good with consistent order flow |
| Research tools / lab supply | Recurring product revenue | Good |
| Pre-revenue / clinical-stage biotech | Grants + equity, little or no deposits | Poor — no revenue to underwrite |
The dividing line is simple: if your business bank account shows a real, repeating pattern of customer deposits, this tool can read it. If your inflows are grant tranches and a Series A, it can't.
Decision framework: works best when / avoid when
A revenue-based line works best when:
- You book consistent monthly deposits — payer reimbursement, sponsor invoices, or product revenue — even if net income is thin.
- You have a specific, closing gap: a signed contract, a confirmed PO, a reimbursement batch in the queue, a two-month payroll bridge.
- A bank line is stalled on covenants, operating history, or collateral you don't want to pledge.
- Speed matters — you need funds in days, not the weeks a bank underwrite takes.
- Owner FICO is below bank thresholds (down to ~500) but the deposits are healthy.
Avoid it (or pair it with something else) when:
- You're pre-revenue or grant-funded — there are no deposits to underwrite against; look at venture debt or non-dilutive grant financing instead.
- You'd be funding a multi-year R&D runway rather than a defined timing gap.
- Your margins can't absorb a daily or weekly remittance without starving reagent and payroll spend — model the cash-flow impact first, not just the headline amount.
- You're already carrying multiple advances and stacking a new one would over-commit deposits. Consolidating the position is the better move.
Documents and timeline: what underwriting actually asks for
The reason this funds in 24-48 hours is that the document ask is short and the analysis is deposit-driven. A typical package:
- 3-6 months of business bank statements — the core of the file; underwriting reads average daily balance, deposit consistency, and negative days.
- A completed one-page application with entity details and ownership.
- Basic KYC — driver's license, voided check or bank verification, and often an EIN document.
- Sometimes a recent A/R aging or a copy of a large contract/PO, especially for CROs and distributors where a single receivable drives the ask.
Notably absent: tax returns are often optional at smaller amounts, and there's no collateral appraisal, no covenant package, and no board resolution. Realistic timeline — for example, statements uploaded Monday morning, offers back the same day, funds Tuesday or Wednesday once verification clears. Clean, complete statements are the single biggest driver of speed; a mid-cycle switch of bank accounts or a stretch of negative days is what slows a file down.
Example scenarios (illustrative, not quotes)
These are for example only — structure and amounts vary by deposits, industry, and time in business. They show the shape of a fit, not a rate quote.
| Company | Situation | How the line is used | Why it fit |
|---|---|---|---|
| Regional diagnostics lab | Payer reimbursement running 75+ days; steady deposits | Bridge reagent + tech payroll between billing and payment | Deposits regular; bank line capped on collateral |
| Mid-size CRO | Won a new sponsor study; ramp costs precede first milestone invoice | Fund study startup and hiring ahead of billing | Recurring sponsor billings support reconciliation |
| Device distributor | Large hospital-system PO; supplier wants deposit up front | Fund inventory purchase against the confirmed PO | Clear, closing PO-to-payment gap |
| Small CDMO | Two-month payroll gap between batch deliveries | Smooth payroll until next batch revenue lands | Consistent order flow; thin net income only |
In each case the common thread is a visible, closing gap backed by real deposits — not open-ended R&D spend.
How to compare offers without getting burned
Once you're approved, the offers you weigh should be judged on cash-flow terms, not a single headline number. As an underwriter I'd tell a founder to ask:
- What's the remittance frequency and amount? Daily vs. weekly changes how it hits your operating account. Match it to when your deposits land.
- Is there true reconciliation? A real revenue-based structure adjusts the remittance to your actual volume. Confirm it in writing.
- What share of deposits is committed? Add it to any existing advance. If total committed deposits crowd out reagents and payroll, the amount is too big — take less.
- Any prepayment benefit? If a big reimbursement batch lands early, can you retire the balance and save?
- Who's actually funding it? A marketplace shops multiple funders against one application, which usually means more offers to compare — but read who the counterparty is.
No legitimate funder can promise approval, and you should treat the word "guaranteed" as a red flag. Approval always depends on what the statements show.
Frequently asked questions
Is this a real line of credit or a merchant cash advance?
For revenue-generating life sciences companies, the practical product is usually a revenue-based advance through an MCA marketplace, which functions like flexible working capital rather than a traditional revolving bank line. Repayment is a fixed share of your deposits that reconciles with your revenue. It behaves like a line for timing gaps, but it is structured as an advance against future receipts — not a bank credit facility with a draw-and-repay revolver.
Can a pre-revenue biotech qualify?
Generally no. This financing is underwritten on business bank deposits and revenue trend. A pre-revenue, grant- or equity-funded clinical-stage biotech has no repeating customer deposits to underwrite against, so it isn't a fit. Those companies are better served by venture debt, non-dilutive grant financing, or equity. This tool is for the operating, revenue-generating side of life sciences.
What credit score do I need?
Owner FICO down to roughly 500 can still be approved, because deposits and revenue carry more weight than credit in this model. A thin or bruised personal credit file that would sink a bank application often clears here, provided the business bank statements show consistent deposits and few negative days.
How fast can we get funded?
Commonly 24-48 hours after complete bank statements are submitted and verification clears. For example, statements uploaded in the morning can produce same-day offers and funding a day or two later. Clean, complete statements are the biggest driver of speed; negative-day stretches or a mid-cycle bank-account switch slow the file down.
What's the minimum amount?
Typically around $10,000 at the low end, scaling up with your deposit volume and time in business. The right amount is the one your cash flow can absorb — model the remittance against reagent, instrument, and payroll spend before accepting the largest offer you're shown.
What documents are required?
Usually three to six months of business bank statements, a one-page application, and basic KYC (ID, voided check or bank verification, often an EIN document). For CROs and distributors, an A/R aging or a copy of a large contract or PO may be requested when a single receivable drives the ask. Tax returns are often optional at smaller amounts.
Will the remittance choke our payroll and reagent spend?
It shouldn't if the amount is sized correctly. Because repayment is a percentage of deposits, it flexes down in slow weeks. The risk comes from taking too large an advance or stacking multiple advances so that committed deposits crowd out operating spend. Add any existing advance to the new one and confirm total committed deposits still leave room for payroll and consumables.
Can you guarantee approval?
No — and no legitimate funder can. Approval always depends on what your bank statements show: deposit consistency, average balance, and negative days. Treat any offer that promises guaranteed approval as a warning sign. A marketplace improves your odds by shopping one application to multiple funders, but the deposits still decide.
